Methylatropine
Chemical compound
- A03BB02 (WHO)
- (1R,5R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane
- 31610-87-4
- 1550101
- DB13833
- 5652
- 80719I460H
- ChEMBL1179176
- Interactive image
- C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
InChI
- InChI=1S/C18H26NO3/c1-19(2)14-8-9-15(19)11-16(10-14)22-18(21)17(12-20)13-6-4-3-5-7-13/h3-7,14-17,20H,8-12H2,1-2H3/q+1/t14-,15+,16?,17-/m0/s1
- Key:PIPAJLPNWZMYQA-WFVVYAPDSA-N
Methylatropine (trade name Eumydrin) is a belladonna derivative.
In 1902, the Bayer Company introduced methylatropine, a quaternary ammonium salt of atropine, as a mydriatic for dilation of the pupil during ophthalmic examination under the brand name of Eumydrin. Because of its highly polar nature it penetrated less readily into the central nervous system than did atropine; hence it was introduced for relieving pyloric spasm in infants.[1]
The blocking potency of methylatropine is approximately 10-20 times higher than that of atropine at neuromuscular and ganglionic synapses.[2]
See also
- Apoatropine
References
- ^ "Methylatropine Bromide". Inxight: Drugs. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, U.S. Department of Health and Human Services.
- ^ Gyermek L (1998). "Semisynthetic Derivatives of Tropane Alkaloids and of other Tropane Esters". Pharmacology of Antimuscarinic Agents. Boca Raton: CRC Press. p. 162. ISBN 978-0-8493-8559-9.
- v
- t
- e
Drugs for functional gastrointestinal disorders (A03)
functional
bowel
disorders
Antimuscarinics |
| ||||
---|---|---|---|---|---|
Phosphodiesterase inhibitors | |||||
Acting on serotonin receptors |
| ||||
Other |
and derivatives
(antimuscarinics)
- Tertiary amines: Atropine
- Hyoscyamine
- Quaternary ammonium compounds:
- Methylatropine
- Fentonium bromide
- Cimetropium bromide
This article incorporates public domain material from Methylatropine Bromide. National Institutes of Health.
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e